ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1707

A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis

Yuqing Wang1, Duolong Zhu1, Laura Ortiz-Velez2, Jacob Perry1, Michael Pennington3, Joseph Hyser1, Robert Britton1 and Christine Beeton1, 1Baylor College of Medicine, Houston, TX, 2TMC Innovation, Houton, 3AmbioPharm Inc., North Augusta, SC

Meeting: ACR Convergence 2021

Keywords: Autoinflammatory diseases, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: CCR7– effector memory T (TEM) lymphocytes are targets for immunomodulation for the treatment of rheumatoid arthritis (RA). Following activation, TEM cells upregulate the expression of the potassium channel Kv1.3, and blocking this channel inhibits TEM cell proliferation and secretion of pro-inflammatory cytokines with minimal effects of CCR7+ naïve and central memory T cells. Analogs of the small peptide ShK, engineered to enhance their selectivity for Kv1.3, are effective in reducing disease severity in animal models of RA and other autoimmune diseases and in patients with active plaque psoriasis. However, like most biologics, these peptides must be injected repeatedly. Here, we propose a novel approach for the delivery of the ShK analog ShK-235 by inducing its production and secretion by a probiotic bacterium, Lactobacillus reuteri, for oral delivery into the gastrointestinal tract.

Methods: We designed LrS235, a bioengineered L. reuteri that secretes the ShK-235 peptide and used a single-cell patch-clamp to quantify ShK-235 in the culture supernatant of LrS235 and in the circulation of healthy rats gavaged with LrS235. We used functional assays to define the effects of ShK-235 secreted by LrS235 on the proliferation of TEM cells in vitro. We next tested the efficacy of LrS235 in two animal models, delayed-type hypersensitivity (DTH) and collagen-induced arthritis (CIA).

Results: Supernatants from LrS235 block Kv1.3 currents and inhibit human TEM cells proliferation and IL-2 and IFN-g production in vitro. A single oral gavage of LrS235 in healthy rats results in sufficient levels of ShK-235 in the circulation to block Kv1.3 channels and reduces inflammation in the DTH model. The daily oral gavage of LrS235 is efficacious in reducing clinical signs of disease and joint inflammation in rats with CIA.

Conclusion: Our results demonstrate the potential of using the probiotic L. reuteri as a novel oral delivery system for ShK-235, and possibly other biologics, to treat RA.


Disclosures: Y. Wang, None; D. Zhu, None; L. Ortiz-Velez, None; J. Perry, None; M. Pennington, AmbioPharm Inc., 10; J. Hyser, AmbioPharm Inc., 10; R. Britton, AmbioPharm Inc., 10, Mikrovia, 12, Co-founder, PanaBio, 12, Co-founder; C. Beeton, AmbioPharm Inc., 10.

To cite this abstract in AMA style:

Wang Y, Zhu D, Ortiz-Velez L, Perry J, Pennington M, Hyser J, Britton R, Beeton C. A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/a-bioengineered-probiotic-for-the-oral-delivery-of-an-immunomodulator-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-bioengineered-probiotic-for-the-oral-delivery-of-an-immunomodulator-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology